The use of anthracyclines and taxane-based chemotherapy regimens, in combination with Trastuzumab and Pertuzumab in the case of human epidermal growth factor receptor 2 (HER2)-positive disease, has shown that depending on the biological BC subtype, nodal involvement can be eradicated in approximately 50–75% of patients [7,13,17,18,19]. This evidence concerns the gene ERBB2 and breast cancer.